Treatment options for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are rapidly advancing, with new approaches reshaping clinical decision-making. In this expert-led discussion, Mr. Ryan Quigley speaks with Dr. Chafic Karam, Professor of Clinical Neurology and Chief of the Neuromuscular Division at the University of Pennsylvania, about the latest FDA-approved therapies—including subcutaneous immunoglobulin and efgartigimod—and the promise of complement inhibition therapies in ongoing trials.